BidaskClub upgraded shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a buy rating to a strong-buy rating in a research note published on Tuesday morning.

TRHC has been the subject of a number of other research reports. CIBC reissued an outperform rating and issued a $47.00 price objective (up previously from $35.00) on shares of Tabula Rasa HealthCare in a report on Tuesday, March 13th. Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a hold rating to a sell rating in a report on Saturday, March 17th. William Blair reaffirmed an outperform rating on shares of Tabula Rasa HealthCare in a report on Tuesday, March 13th. Citigroup assumed coverage on shares of Tabula Rasa HealthCare in a report on Thursday, January 4th. They set a buy rating for the company. Finally, Oppenheimer upped their price target on shares of Tabula Rasa HealthCare from $35.00 to $47.00 and gave the stock an outperform rating in a report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and an average target price of $36.40.

NASDAQ TRHC opened at $40.98 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $795.54, a price-to-earnings ratio of -1,024.50, a price-to-earnings-growth ratio of 8.83 and a beta of 2.39. Tabula Rasa HealthCare has a 12-month low of $11.59 and a 12-month high of $42.79.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Monday, March 12th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.03). The business had revenue of $43.93 million during the quarter, compared to the consensus estimate of $38.91 million. Tabula Rasa HealthCare had a net margin of 10.63% and a negative return on equity of 1.96%. The business’s revenue for the quarter was up 60.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. research analysts forecast that Tabula Rasa HealthCare will post 0.18 EPS for the current fiscal year.

In related news, Director Bruce Luehrs sold 252,242 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $34.29, for a total transaction of $8,649,378.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $35.59, for a total transaction of $284,720.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 324,000 shares of company stock valued at $11,309,958. 45.80% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its position in Tabula Rasa HealthCare by 79.8% during the 3rd quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock worth $341,000 after purchasing an additional 5,668 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Tabula Rasa HealthCare during the 3rd quarter worth approximately $563,000. EAM Investors LLC increased its position in Tabula Rasa HealthCare by 21.5% during the 4th quarter. EAM Investors LLC now owns 178,588 shares of the company’s stock worth $5,009,000 after purchasing an additional 31,596 shares in the last quarter. Pier Capital LLC increased its position in Tabula Rasa HealthCare by 33.3% during the 4th quarter. Pier Capital LLC now owns 206,905 shares of the company’s stock worth $5,804,000 after purchasing an additional 51,673 shares in the last quarter. Finally, Quadrant Private Wealth Management LLC acquired a new position in Tabula Rasa HealthCare during the 4th quarter worth approximately $569,000. Institutional investors and hedge funds own 47.06% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to enhance patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.